Population genetics of BRCA1 and BRCA2.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

117 citing papers in PubMed.

1. Testing for hereditary breast and ovarian cancer in the southeastern United States.Annals of surgery · 2000
   Trial
2. Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India.Indian journal of surgical oncology · 2023
   Article
3. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Annals of surgical oncology · 2023
   Article
4. Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.International journal of environmental research and public health · 2022
   Article
5. BRCA1: An Endocrine and Metabolic Regulator.Frontiers in endocrinology · 2022
   Review
6. Prognostic Impact ofBiology · 2021
   Article
7. A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.Clinical Medicine Insights. Oncology · 2021
   Article
8. Prevalence and Spectrum ofGenes · 2020
   Article
9. Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy.International journal of molecular sciences · 2020
   Review
10. Geographic assessment of cancer genome profiling studies.Database : the journal of biological databases and curation · 2020
    Article
11. Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer.Frontiers in oncology · 2020
    Article
12. Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2019
    Article
13. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis inCancers · 2019
    Article
14. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants.Cancers · 2018
    Review
15. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.BMC cancer · 2018
    Article
16. Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast TumorsIranian biomedical journal · 2018
    Article
17. Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.Breast cancer research and treatment · 2017
    Article
18. High Resolution Melting Analysis is Very Useful to Identify BRCA1 c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA.Molecular diagnosis & therapy · 2017
    Article
19. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.PloS one · 2017
    Article
20. Characterization ofF1000Research · 2017
    Article

57 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.1997
• Comment on
  BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.1997
• Comment on
  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.1997
• Comment on
  A low proportion of BRCA2 mutations in Finnish breast cancer families.1997
• Comment on
  Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.1997
• Comment on
  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.1997
• Comment on
  Study of a single BRCA2 mutation with high carrier frequency in a small population.1997

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as